Literature DB >> 2847595

The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats.

J Church1, S Zeman, D Lodge.   

Abstract

The neuroprotective activity of two systemically administered N-methyl-D-aspartate (NMDA) receptor antagonists, ketamine and MK-801, were investigated in a long-term recovery model of near-complete forebrain ischemia in the rat. Doses of each drug were chosen on the basis of the known degree and time course of NMDA antagonism seen in vivo after their systemic administration. Ketamine, administered at a dose of 20 mg.kg-1 iv, either immediately before or shortly after the 10-min ischemic period, failed to lessen neuronal damage in the selectively vulnerable hippocampal CA1 region. Increasing doses of ketamine administered over an increasing length of time in the postischemic period, however, did provide significant protection. MK-801 0.25 or 0.5 mg.kg-1 iv administered before ischemia also resulted in significant protection. The results support the proposal that NMDA receptor-mediated events may contribute to neuronal damage in selectively vulnerable regions of the central nervous system after ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847595     DOI: 10.1097/00000542-198811000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

1.  The Epidural and Intrathecal Administration of Ketamine.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

2.  Ketamine concentrations during cardiopulmonary bypass.

Authors:  R F McLean; A J Baker; S E Walker; C D Mazer; B I Wong; E M Harrington
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

Review 3.  [Role of ketamine in sepsis and systemic inflammatory response syndrome].

Authors:  M Lange; K Bröking; H van Aken; C Hucklenbruch; H-G Bone; M Westphal
Journal:  Anaesthesist       Date:  2006-08       Impact factor: 1.041

Review 4.  Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection.

Authors:  R Hall; J Murdoch
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

Review 5.  Ketamine: review of its pharmacology and its use in pediatric anesthesia.

Authors:  S A Bergman
Journal:  Anesth Prog       Date:  1999

6.  Dose-dependent effects of repeated ketamine administration on muscarinic acetylcholine receptors in the mouse forebrain.

Authors:  Shinichiro Hitomi; Toshihito Morita; Shigeru Saito; Yoshitaka Uchihashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

Review 7.  Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury.

Authors:  J Murdoch; R Hall
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

Review 8.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

9.  Ketamine and strychnine treatment of an infant with nonketotic hyperglycinaemia.

Authors:  H Tegtmeyer-Metzdorf; B Roth; M Günther; M Theisohn; U Heinemann; H A Adams; G Sticht
Journal:  Eur J Pediatr       Date:  1995-08       Impact factor: 3.183

10.  Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice.

Authors:  T Morita; S Hitomi; S Saito; T Fujita; Y Uchihashi; H Kuribara
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.